Mannatech Appoints James Clavijo As CFO, Effective July 1, 2024
$MTEX
Medicinal Chemicals and Botanical Products
Health Care
Mannatech Appoints James Clavijo As CFO, Effective July 1, 2024
Save time and jump to the most important pieces.
Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal
Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c
Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr
Mannatech, Incorporated (NASDAQ:MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 6, 2023. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting and David Johnson, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2022 and the first quarter of 2023. There were 1,872,422 outstanding shares of Mannatech's common stock as of April 20, 2023 entitled to vote and 1,270,511 shares, or approximately 67.9% represe
Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply
Q1 2024 EPS of $0.63 vs. $0.32 in Q1 2023 Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2024. First Quarter Highlights Net sales for the quarter ended March 31, 2024 were $29.4 million, as compared to $34.1 million for the same period in 2023, a decrease of $4.7 million, or 13.8%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $3.9 million, or 11.3%, and unfavorable foreign exchange caused a $0.8 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principal
Mannatech, Incorporated (NASDAQ:MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter and year ended December 31, 2023. Fourth Quarter Highlights Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022. Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials. Operating loss in the fourth quarter was $0.9 million, improved from an operating loss
4 - MANNATECH INC (0001056358) (Issuer)
SC 13G - MANNATECH INC (0001056358) (Subject)
SC 13G/A - MANNATECH INC (0001056358) (Subject)
SC 13G/A - MANNATECH INC (0001056358) (Subject)
4 - MANNATECH INC (0001056358) (Issuer)
4 - MANNATECH INC (0001056358) (Issuer)
4/A - MANNATECH INC (0001056358) (Issuer)
8-K - MANNATECH INC (0001056358) (Filer)
8-K - MANNATECH INC (0001056358) (Filer)
8-K - MANNATECH INC (0001056358) (Filer)
Mannatech (NASDAQ:MTEX) reported quarterly earnings of $0.63 per share. This is a 96.88 percent increase over earnings of $0.32 per share from the same period last year. The company reported $29.39 million in sales this quarter. This is a 13.84 percent decrease over sales of $34.11 million the same period last year.
Mannatech (NASDAQ:MTEX) reported quarterly losses of $(0.94) per share. This is a 75.13 percent increase over losses of $(3.78) per share from the same period last year. The company reported $32.69 million in sales this quarter. This is a 4.78 percent decrease over sales of $34.34 million the same period last year.